loading
Schlusskurs vom Vortag:
$14.47
Offen:
$14.35
24-Stunden-Volumen:
420.03K
Relative Volume:
0.29
Marktkapitalisierung:
$2.08B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-5.0316
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
-1.22%
1M Leistung:
-0.33%
6M Leistung:
-35.41%
1J Leistung:
-39.21%
1-Tages-Spanne:
Value
$14.14
$14.56
1-Wochen-Bereich:
Value
$13.70
$14.85
52-Wochen-Spanne:
Value
$10.57
$33.33

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name
Firmenname
Denali Therapeutics Inc
Name
Telefon
(650) 866-8547
Name
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Name
Mitarbeiter
443
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
DNLI's Discussions on Twitter

Vergleichen Sie DNLI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DNLI
Denali Therapeutics Inc
14.34 2.01B 340.81M -419.65M -402.10M -2.85
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Hochstufung Cantor Fitzgerald Neutral → Overweight
2025-03-07 Fortgesetzt Morgan Stanley Overweight
2025-02-11 Eingeleitet Deutsche Bank Buy
2025-01-07 Eingeleitet Robert W. Baird Outperform
2025-01-03 Eingeleitet William Blair Outperform
2024-12-16 Hochstufung Stifel Hold → Buy
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-10-07 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-12-13 Eingeleitet Citigroup Buy
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-09-06 Eingeleitet B. Riley Securities Buy
2023-01-30 Eingeleitet SVB Securities Outperform
2022-12-05 Eingeleitet Cowen Outperform
2022-11-02 Hochstufung BTIG Research Neutral → Buy
2022-11-02 Eingeleitet BofA Securities Buy
2022-06-23 Eingeleitet Berenberg Buy
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-09-21 Eingeleitet Oppenheimer Outperform
2021-09-01 Eingeleitet SMBC Nikko Outperform
2021-05-18 Eingeleitet UBS Buy
2021-02-26 Bestätigt H.C. Wainwright Buy
2021-02-10 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-11-11 Bestätigt H.C. Wainwright Buy
2020-10-16 Herabstufung BTIG Research Buy → Neutral
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-20 Bestätigt H.C. Wainwright Buy
2020-03-13 Hochstufung Evercore ISI In-line → Outperform
2020-02-28 Hochstufung Wedbush Neutral → Outperform
2020-02-24 Eingeleitet Jefferies Buy
2020-02-19 Eingeleitet Stifel Hold
2020-01-27 Hochstufung Goldman Neutral → Buy
2019-09-26 Eingeleitet Wedbush Neutral
2019-09-13 Eingeleitet Nomura Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-06-26 Eingeleitet H.C. Wainwright Buy
2018-11-15 Eingeleitet Cantor Fitzgerald Overweight
2018-11-12 Eingeleitet Janney Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-01-02 Eingeleitet Evercore ISI Outperform
2018-01-02 Eingeleitet Goldman Neutral
2018-01-02 Eingeleitet JP Morgan Overweight
2018-01-02 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten

pulisher
Jul 23, 2025

What analysts say about Denali Therapeutics Inc. stockOutstanding capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Denali Therapeutics Inc. stock priceFree Technical Analysis Support - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Denali Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Denali Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 19, 2025

What makes Denali Therapeutics Inc. stock price move sharply3x Return Stock Radar - beatles.ru

Jul 19, 2025
pulisher
Jul 19, 2025

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN

Jul 19, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 15, 2025

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 11, 2025

Denali Therapeutics' Insider Sale: Routine Diversification or a Cause for Concern? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

DNLI SEC FilingsDenali Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 11, 2025
pulisher
Jul 08, 2025

FDA accepts priority review for Denali’s Hunter syndrome therapy By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

FDA accepts priority review for Denali’s Hunter syndrome therapy - Investing.com Australia

Jul 08, 2025
pulisher
Jul 08, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Factor Thisâ„¢ Energy Understood. All Factored In. - FinancialContent

Jul 07, 2025
pulisher
Jun 30, 2025

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Jun 30, 2025
pulisher
Jun 26, 2025

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Jun 26, 2025
pulisher
Jun 24, 2025

(DNLI) Proactive Strategies - news.stocktradersdaily.com

Jun 24, 2025
pulisher
Jun 23, 2025

Denali Therapeutics stock poised for catalyst as FDA decision nears By Investing.com - Investing.com South Africa

Jun 23, 2025
pulisher
Jun 13, 2025

(DNLI) Investment Analysis - news.stocktradersdaily.com

Jun 13, 2025
pulisher
Jun 10, 2025

Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

Denali Therapeutics Enters Registration Rights Agreement - TipRanks

Jun 03, 2025
pulisher
Jun 01, 2025

(DNLI) On The My Stocks Page - news.stocktradersdaily.com

Jun 01, 2025
pulisher
May 31, 2025

Q2 EPS Estimate for Denali Therapeutics Boosted by Analyst - Defense World

May 31, 2025
pulisher
May 30, 2025

Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

May 30, 2025
pulisher
May 29, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia

May 29, 2025

Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Denali Therapeutics Inc-Aktie (DNLI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Watts Ryan J.
President and CEO
Jul 09 '25
Sale
15.00
495,282
7,429,230
253,071
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):